Citi analyst Robyn Karnauskas initiates coverage on Tocagen Inc. (NASDAQ: TOCA) with a Buy rating and a price target of $27.00.

The analyst is positive on the name ahead of brain cancer data and likes the innovative platform.

For an analyst ratings summary and ratings history on Tocagen Inc. click here. For more ratings news on Tocagen Inc. click here.

Shares of Tocagen Inc. closed at $9.75 yesterday.